192 related articles for article (PubMed ID: 17051166)
1. AIDS and the private sector.
Nature; 2006 Oct; 443(7113):723. PubMed ID: 17051166
[No Abstract] [Full Text] [Related]
2. A corporate response to AIDS.
Nature; 2007 Jan; 445(7124):125. PubMed ID: 17215807
[No Abstract] [Full Text] [Related]
3. Shifting the burden: the private sector's response to the AIDS epidemic in Africa.
Rosen S; Simon JL
Bull World Health Organ; 2003; 81(2):131-7. PubMed ID: 12751421
[TBL] [Abstract][Full Text] [Related]
4. A firm response to AIDS.
Nature; 2006 Oct; 443(7113):738-9. PubMed ID: 17051178
[No Abstract] [Full Text] [Related]
5. Secure the future--seeking solutions through partnership.
Wanless SR
SADJ; 2002 Dec; 57(11):437-8. PubMed ID: 12674857
[No Abstract] [Full Text] [Related]
6. Firms seek new models to access public equity.
Mitchell P
Nat Biotechnol; 2009 Oct; 27(10):878-9. PubMed ID: 19816432
[No Abstract] [Full Text] [Related]
7. Public sector seeks to bridge 'valley of death'.
Moran N
Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
[No Abstract] [Full Text] [Related]
8. Public-private partnerships in drug development for underdeveloped countries: an interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division. Interview by Thomasine Kushner.
Wheeler C
Camb Q Healthc Ethics; 2003; 12(4):429-33. PubMed ID: 14619375
[No Abstract] [Full Text] [Related]
9. Public-private partnerships in health care for developing countries: a new paradigm for change.
Ahn M; Herman A; Damonti J
Manag Care Q; 2000; 8(4):65-72. PubMed ID: 11146847
[TBL] [Abstract][Full Text] [Related]
10. Human genomes, public and private.
Nature; 2001 Feb; 409(6822):745. PubMed ID: 11236960
[No Abstract] [Full Text] [Related]
11. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
12. The Human Genome Project: a public good.
Hudson K
Health Matrix Clevel; 2002; 12(2):367-75. PubMed ID: 12430360
[No Abstract] [Full Text] [Related]
13. Issues in AIDS services delivery: a symposium. Introduction.
Liou KT
J Health Hum Serv Adm; 1997; 19(3):235-9. PubMed ID: 10168165
[No Abstract] [Full Text] [Related]
14. [Does the public sector have an independent research role in the development of drugs?].
Poulsen HE; Grønlykke TB
Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
[TBL] [Abstract][Full Text] [Related]
15. Eurofile. Private-public drive to cut delays in drug development.
Mundell I
Eur J Cancer; 2008 Jan; 44(2):169. PubMed ID: 18335586
[No Abstract] [Full Text] [Related]
16. HIV/AIDS. The Global Fund's best friend?
Cohen J
Science; 2008 Jul; 321(5888):524. PubMed ID: 18653881
[No Abstract] [Full Text] [Related]
17. Proportion of private sector spending declining.
Buske L
CMAJ; 2002 Feb; 166(4):498. PubMed ID: 11873937
[No Abstract] [Full Text] [Related]
18. Facing the challenge: the symposium in context.
Widdus R
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S30-2. PubMed ID: 16087205
[No Abstract] [Full Text] [Related]
19. Brazil's fight against AIDS and its implications for global health governance.
Wogart JP; Calcagnotto G
Healthc Q; 2006; 9(1):76-89. PubMed ID: 16548439
[TBL] [Abstract][Full Text] [Related]
20. A lifeline for the biotech sector.
Kessel M
Nat Biotechnol; 2009 Feb; 27(2):123-4. PubMed ID: 19204686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
